Rising sales of drugs for cancer and heart disease helped offset steep declines for Pfizer’s Covid-19 products.

July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration had granted priority review to its application seeking expanded approval for its prostate cancer treatment ...

Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which ...

Talzenna plus Xtandi is already approved in the U.S. to treat men with HRR gene-mutated metastatic castration-resistant prostate cancer. If approved, the expanded label would allow the therapy to be ...

Q2 operational sales growth of 1% was driven by higher sales of older medicines, including cancer drug Padcev (+23% ...